EFFECTIVENESS AND SAFETY OF LENVATINIB AND PEMBROLIZUMAB (LENPEM) THERAPY FOR ENDOMETRIAL CANCER (EC): RESULTS FROM A RUSSIAN MULTICENTER DATABASE

被引：0
|
作者：
Tyulyandina, A. [1 ,2 ]
Kedrova, A. [3 ,4 ]
Graft, N. [5 ]
Ibragimova, M. [6 ]
Krashikhina, T. [7 ]
Zhelezkova, T. [8 ]
Vasilieva, J. [8 ]
Maistrenko, K. [9 ]
Kuchevskaya, O. [9 ]
Markizova, E. [9 ]
Stradaeva, I. [10 ]
Markarova, E. [11 ]
Belonogov, A. [12 ]
Ibragomov, T. [13 ]
Zorina, E. [13 ]
Luev, I. [8 ]
Zhikhorev, R. [8 ]
Popova, M. [5 ]
Vlasova, L. [9 ]
Volkonsky, M. [8 ]
机构：
[1] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[2] IM Sechenov First Moscow State Med Univ Sechenov, Moscow, Russia
[3] Fed Sci Clin Ctr Specialized Types Med Care & Med, Moscow, Russia
[4] Acad Postgrad Educ FSBU FSCC FMBA, Moscow, Russia
[5] Moscow Clin Inst Sci Ctr, Moscow, Russia
[6] Moscow City Oncol Hosp 1, Moscow, Russia
[7] Lyadov Clin, Moscow, Russia
[8] Moscow City Oncol Hosp 62, Moscow, Russia
[9] Moscow City Clin Hosp 40, Moscow, Russia
[10] PET Technol Clin, Moscow, Russia
[11] Moscow Reg Res & Clin Inst, Moscow, Russia
[12] Odintsovo Cent Reg Hosp, Moscow, Russia
[13] Podolsk Oncol Dispensary, Moscow, Russia
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷
关键词：
D O I：
10.1136/ijgc-2021-ESGO.197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
791
引用
收藏
页码：A123 / A124
页数：3
相关论文
共 50 条
  • [1] Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
    Makker, V.
    Taylor, M. H.
    Aghajanian, C.
    Oaknin, A.
    Mier, J.
    Cohn, A. L.
    Romeo Marin, M.
    Bratos Lorenzo, R.
    Brose, M. S.
    DiSimone, C.
    Messing, M. J.
    Stepan, D. E.
    Dutcus, C. E.
    Wu, J.
    Schmidt, E. V.
    Orlowski, R. J.
    Sachdev, P.
    Shumaker, R.
    Casado Herraez, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 404 - +
  • [2] Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
    Mimura, Kaito
    Shimomura, Akihiko
    Gota, Tomoko
    Ando, Kenju
    Kawamura, Yukino
    Taniyama, Tomoko
    Oishi, Hajime
    Shimizu, Chikako
    [J]. GYNECOLOGIC ONCOLOGY REPORTS, 2022, 44
  • [3] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Updated results
    Makker, Vicky
    Rasco, Drew
    Vogelzang, Nicholas J.
    Messing, Mark
    Brose, Marcia S.
    Cohn, Allen L.
    Aghajanian, Carol
    Stepan, Daniel E.
    Dutcus, Corina
    Schmidt, Emmett
    Guo, Matthew
    Sachdev, Pallavi
    Shumaker, Robert
    Young, Louise
    Taylor, Matthew
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 175 - 175
  • [4] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Updated results.
    Makker, Vicky
    Rasco, Drew W.
    Vogelzang, Nicholas J.
    Messing, Mark
    Brose, Marcia S.
    Cohn, Allen Lee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis
    Barrington, David
    Calhoun, Cody
    Haight, Paulina
    Tubbs, Crystal
    Cohn, David
    Bixel, Kristin
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S35 - S35
  • [6] Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
    Barrington, David A.
    Haight, Paulina J.
    Calhoun, Cody
    Tubbs, Crystal
    Cohn, David E.
    Bixel, Kristin L.
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 (03) : 626 - 630
  • [7] Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea
    Kim, Junhwan
    Noh, Joseph J.
    Lee, Tae Kyoung
    Kim, Se Ik
    Lee, Jung-Yun
    Lee, Jeong-Won
    Kim, Jae-Weon
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 165 (02) : 369 - 375
  • [8] Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775
    Yonemori, Kan
    Yunokawa, Mayu
    Ushijima, Kimio
    Sakata, Jun
    Shikama, Ayumi
    Minobe, Shinichiro
    Usami, Tomoka
    Enomoto, Takayuki
    Takehara, Kazuhiro
    Hasegawa, Kosei
    Yamagami, Wataru
    Yamamoto, Keiko
    Han, Shirong
    Dutta, Lea
    Orlowski, Robert
    Miura, Takuma
    Makker, Vicky
    Fujiwara, Keiichi
    [J]. CANCER SCIENCE, 2022, 113 (10) : 3489 - 3497
  • [9] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Cohn, Allen L.
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    Di Simone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett V.
    Orlowski, Robert
    McKenzie, Jodi A.
    Gillis, Kathryn
    Young, Louise
    Herraez, Antonio Casado
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 134
  • [10] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Lee Cohn, Allen
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    DiSimone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett, V
    Orlowski, Robert
    Alicia McKenzie, Jodi
    Gillis, Kathryn
    Casado Herraez, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345